Solstice Advanced Materials posted 11% revenue growth in 2Q26 and raised full-year guidance, with refrigerants, electronic materials and nuclear services driving the story. Leverage, margin pressure and the Element Solutions deal keep the risk profile elevated.
Solstice Advanced Materials (SOLS) merits a Buy rating for moderate-risk investors seeking medium-term exposure to specialty chemicals, semiconductor materials, low-global-warming-potential refrigerants and nuclear infrastructure. The investment case rests on three hard facts: 2Q26 revenue rose 11% to $1.15B, adjusted diluted EPS reached $0.88, and management raised full-year 2026 guidance after the quarter.
The strongest growth engines are Electronic Materials, refrigerants and nuclear conversion services. Electronic Materials sales increased 15% to $119M in 2Q26, refrigerants rose 13% to $473M, and nuclear sales climbed 27% to $125M. These businesses connect SOLS to semiconductor production, data center cooling, regulatory refrigerant conversion and renewed nuclear investment.
The case is not risk-free. RAS adjusted EBITDA margin fell to 32.9% in 2Q26 from 39.4% a year earlier, 2025 net income was $237M versus $718M in 2022, and total debt stood at $2.33B at June 30, 2026. The announced Element Solutions transaction could broaden the platform, but it also adds execution and financing complexity. A $72.00 fair value estimate reflects attractive growth assets while applying a discount for leverage, cyclicality and transaction risk.
Solstice Advanced Materials (SOLS) is a U.S.-based specialty chemicals and advanced materials company headquartered in Morris Plains, New Jersey. The company operates through Refrigerants & Applied Solutions (RAS) and Electronic & Specialty Materials (ESM), serving HVAC/R, automotive, nuclear energy, semiconductors, defense, pharmaceuticals, healthcare packaging and construction.
SOLS became an independent public company after the Honeywell spin-off completed on October 30, 2025. Honeywell shareholders received one SOLS share for every four Honeywell shares held, resulting in the distribution of 158.7M shares. The company trades on Nasdaq under the ticker SOLS and reported approximately 4,100 employees at December 31, 2025.
The operating footprint includes 20 manufacturing sites, four standalone research and development sites and customers in approximately 120 countries and territories. The 2025 annual filing identified more than 5,700 issued patents and pending applications, along with more than 300 technologists and engineers. That combination gives SOLS a technical base that is more substantial than its relatively recent public listing suggests.
The company reported $3.89B of 2025 revenue and serves more than 3,000 customers. Its brands include Solstice and Genetron in refrigerants, Aclar in healthcare packaging, and Spectra, Fluka and Hydranal in electronic, fiber and laboratory applications.
RAS is the larger and more profitable operating segment. It generated $850M of 2Q26 sales, up 12% year over year, and $280M of adjusted EBITDA. The margin was 32.9%, pressured by heavy plant turnarounds and the timing of prior-year production incentive credits. Management expects RAS adjusted EBITDA margins in the mid-30% range during the second half of 2026.
ESM generated $298M of 2Q26 sales, up 8%, and $64M of adjusted EBITDA, up 24%. Its adjusted EBITDA margin expanded to 21.6% from 18.8%. Electronic Materials led the segment with 15% sales growth, while Safety & Defense Solutions rose 7% and Research & Performance Chemicals increased 3%.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship product family is the Solstice line of HFO refrigerants. These products help customers replace higher-GWP HFCs while maintaining cooling performance. The 454B transition is already supporting demand, and management said North American HFO aftermarket adoption has not fully started. That creates a regulatory replacement cycle with a second leg still ahead.
Automotive refrigerants provide another established product platform. SOLS supplies R-1234yf for conventional, hybrid and electric vehicles, with electric and hybrid vehicles using up to twice the refrigerant volume of traditional combustion vehicles according to the company filing. The product benefits from regulatory requirements in the U.S., Europe, Japan and South Korea, while China represents a further adoption market.
Data center cooling is smaller than the overall refrigerants business but is its fastest-growing component. Management described strong double-digit growth, with current demand concentrated in standard chiller systems. Two-phase direct-to-chip and immersion cooling are still development opportunities rather than the main source of present sales.
Aclar high-barrier films are the flagship healthcare packaging product. The company states that Aclar provides the highest moisture barrier among clear thermoplastic films while protecting medicine efficacy. Solstice Air, an HFO-1234ze(E) medical propellant, can reduce greenhouse gas emissions by up to 99.9% compared with current inhaler propellants.
SOLS has a defensible innovation model because its products sit inside regulated, qualification-heavy or technically demanding applications. The 2025 filing cited more than 5,700 issued patents and pending applications, four standalone R&D sites and a dedicated global team of more than 300 technologists and engineers.
Innovation is already connected to revenue. New products launched during the prior five years contributed 50% of 2025 sales. That figure supports the view that R&D is not merely an expense line. It is a mechanism for keeping customers inside SOLS product platforms as regulations and production technologies change.
The Electronic Materials business is developing copper manganese sputtering targets and expanding its Spokane facility to meet semiconductor demand. SK Hynix recently recognized SOLS with a top supplier award. That award does not guarantee future volume, but it is a concrete validation of supplier reliability and technical execution.
The announced Element Solutions transaction could extend this advantage by combining SOLS chemistry capabilities with Element formulation expertise. The transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals. The opportunity is meaningful, but the benefit depends on integration discipline rather than the announcement itself.
Operational execution improved through a difficult 2Q26 maintenance schedule. Management described the quarter as the company's most significant outage period, including a turnaround at the Metropolis nuclear facility. All sites were operating after the work, and management expects only smaller planned outages in the fall.
Working capital management supported $461M of operating cash flow during the first half of 2026. The company reduced dollar inventory despite higher revenue and rising input costs. First-half free cash flow was $248M, while capital expenditures reached $186M, up 32% from the prior-year period.
Growth capital is moving toward areas with identifiable customer demand. SOLS is expanding electronic materials capacity in Spokane, Spectra ballistic fiber capacity in Virginia and nuclear conversion capacity at Metropolis. Full-year 2026 capital expenditure guidance is $420M to $440M, a substantial investment relative to the company's 2025 free cash flow of $103M.
The supply chain has useful customer-proximity features, with manufacturing across 20 sites and a strong U.S. footprint. That footprint supports supply assurance in semiconductors, nuclear energy and cooling. It also leaves SOLS exposed to energy prices, raw-material costs, logistics interruptions and the operational risks that come with a capital-intensive chemical network.
SOLS participates in several markets rather than one clean category. Third-party estimates place the broad commodity chemicals market near $800B to $900B in 2025, with projected growth estimates ranging from approximately 4% to 6.5% annually. That broad market is a useful scale reference, but SOLS is positioned toward higher-value specialty and advanced materials within it.
The most attractive market structure is the HFO refrigerant transition. Regulation is forcing customers to redesign or replace older refrigerant systems, creating demand for products that meet lower-GWP standards without requiring a complete abandonment of existing equipment. SOLS reported 13% refrigerant sales growth in 2Q26 and expects RAS margins to improve as the aftermarket develops.
Semiconductor materials offer a second secular market. SOLS reported 15% growth in Electronic Materials during 2Q26, while deposition and thermal solutions each grew more than 25% according to the investor presentation. Artificial intelligence and data center investment are supporting semiconductor production, although semiconductor demand remains cyclical and customer qualification can delay the payoff from new capacity.
Nuclear conversion is a smaller but strategically important market. The company's approximately $2.2B nuclear backlog and supply agreements with three small modular reactor developers provide stronger visibility than a spot-market chemical business. Healthcare packaging adds a more defensive market exposure through pharmaceutical and medical applications.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
SOLS served more than 3,000 customers across approximately 120 countries and territories in 2025. No customer represented more than 10% of total sales, and the ten largest customers accounted for less than 20%. The distribution reduces the risk that one account controls the entire investment case.
Customer relationships are also long-lived. Average customer tenure is approximately 10 years, and many large accounts have worked with the company for several decades. RAS alone serves more than 700 customers, with no single RAS customer representing more than 5% of total company sales in 2025.
Contract structures provide useful revenue visibility. Refrigerants and Building Solutions contracts often run from one to five years, aftermarket agreements can run from one to three years, and healthcare agreements can extend to ten years or more. Some contracts include minimum purchase obligations, although fixed pricing and cost-recovery terms can also limit the speed at which margin changes flow through.
The customer base spans original equipment manufacturers, aftermarket wholesalers, pharmaceutical packaging producers, utilities, semiconductor manufacturers, defense customers and government agencies. This mix gives SOLS exposure to both recurring replacement demand and project-driven industrial demand.
RAS competes with Arkema, Chemours, Daikin and Orbia, along with regional producers and technologies that can reduce the need for conventional refrigerants. The competitive advantage of SOLS is strongest where regulatory compliance, product qualification and manufacturing reliability matter more than lowest-cost volume.
The company's position is less comparable to a single-product chemical peer because it combines refrigerants, nuclear conversion, semiconductor materials, protective fibers and healthcare packaging. That mix creates diversification, but it also makes the stock harder to value with a simple sector multiple. The market is being asked to price a portfolio of niche positions rather than one uniform business.
SOLS has advantages in brands, customer proximity and specialized manufacturing. Its risks are equally concrete: competitors can add capacity, substitute technologies can gain adoption, and large customers can pressure pricing. The 2Q26 contrast between RAS sales growth of 12% and RAS adjusted EBITDA decline of 6% shows that technical leadership does not eliminate operating leverage or mix risk.
The Element Solutions acquisition would increase exposure to electronics and formulation capabilities. It could strengthen the competitive platform, but it also raises the standard for management execution because the transaction must deliver commercial and operating benefits while the combined company manages higher leverage.
The macro backdrop is mixed. Commodity chemical markets face overcapacity, thin margins, cyclical construction demand and pressure from large Asian production bases. Energy and feedstock costs remain important because chemicals and petrochemicals account for approximately 40% of U.S. industrial energy use.
Regulation is a more favorable force for SOLS than for an undifferentiated producer. HFO adoption, lower-emission medical propellants and energy-efficiency requirements support demand for products designed around environmental compliance. Regulation can still create risk through product restrictions, compliance costs and changes in the approved chemistry landscape.
Nuclear policy provides a distinct geopolitical tailwind. Executive Order 14302 directed the U.S. Department of Energy to develop a plan to expand domestic uranium conversion capacity. The Department of Energy is sharing certain costs connected with expansion at the AES Facility, while the company is also receiving positive feedback from the Department of Energy and Nuclear Regulatory Commission.
Trade restrictions, shipping disruption and regional industrial policy remain material risks because SOLS serves customers globally and operates across international markets. A U.S.-centered production footprint helps with reshoring demand, but global customers and suppliers still expose the company to currency, tariffs and cross-border logistics.
Total debt stood at $2.33B at June 30, 2026, leaving leverage as a meaningful offset to the company’s growth momentum.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →2Q26 revenue rose 11% to $1.15B and adjusted diluted EPS reached $0.88, but RAS margin still slipped to 32.9% from 39.4% a year earlier.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised full-year 2026 guidance after the quarter, signaling that refrigerants, electronic materials and nuclear demand are running ahead of prior expectations.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →A $72.00 fair value estimate balances attractive growth assets against cyclicality, leverage and the added complexity of the Element Solutions transaction.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s $72 fair value sits between a $56 Buy level and an $88 Sell level, implying the shares are priced for solid growth but not a full rerating.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →SOLS is a credible specialty materials growth story, not a simple commodity chemical trade. The company has regulatory exposure through HFO refrigerants, technical barriers in semiconductor materials, long-duration nuclear demand and defensive healthcare packaging applications.
The latest quarter strengthened the case. Revenue rose 11%, adjusted EPS reached $0.88, ESM adjusted EBITDA rose 24% and management raised full-year guidance. The balance sheet and historical margin record keep the stock from earning a top-tier grade, but the 1.3x reported net leverage, $1.75B of liquidity and improving earnings outlook provide a workable foundation.
The Buy recommendation depends on patience. The strongest returns would come from execution across the Spokane, Virginia and Metropolis expansions, continued refrigerant conversion and successful integration of Element Solutions. Until those investments translate into sustained margins and lower leverage, SOLS is best treated as a measured growth holding rather than a low-volatility compounder.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Solstice Advanced Materials Inc. (SOLS) climbs after ending its planned $14.5 billion merger with Element Solutions and unveiling a $500 million share repurchase. The move reflects relief over reduced deal risk, plus support from recent earnings growth and a stronger standalone capital-allocation story.
Solstice Advanced Materials Inc. (SOLS) climbed after-hours after ending its merger with Element Solutions and authorizing a $500 million share repurchase. The move reflects a sharp strategic reset, with investors refocusing on Solstice’s standalone value, recent earnings strength, and capital return plans.
SOLS looks like a stock getting punished for deal shock more than for a broken core business. The acquisition risk is real, but the selloff has run ahead of a company that just posted 10% quarterly sales growth, reaffirmed guidance, and still carries constructive analyst support.